Does Wegovy increase the risk of cancer — what the evidence actually says

The thyroid question: where the concern comes from

Every conversation about GLP-1 medicines and cancer tends to start in the same place: rats. In pre-clinical studies, high doses of semaglutide given to rodents over long periods produced C-cell tumours in the thyroid, a finding that led to a cautionary note in the prescribing information. It sounds alarming. But rodent thyroid C-cells respond to GLP-1 stimulation differently from human ones, and the doses used in those studies were far higher, relative to body weight, than anything used in people.

Across the large-scale STEP trials (which together involved thousands of adults tracked for up to 68 weeks) no increase in thyroid cancer cases was detected in the semaglutide groups compared with placebo. The NHS medicines page for semaglutide notes that medullary thyroid carcinoma is listed as a contraindication precisely because the theoretical risk cannot be fully dismissed in that specific population, not because it has been observed in the general one. The MHRA considered all of this evidence before granting UK marketing authorisation for Wegovy.

What this means in practice: for most adults, the animal-study findings do not translate into a clinical reason to avoid Wegovy. But if you or a close blood relative has a history of MTC or MEN2, treatment with semaglutide is not appropriate. That is a firm contraindication, not a preference, your prescriber will screen for it. You can read more about how dosing decisions interact with your medical history on our Wegovy doses overview.

Pancreatic cancer: separating association from causation

A second cancer question that comes up regularly involves the pancreas. GLP-1 receptor agonists as a class have been studied in relation to both pancreatitis and, separately, pancreatic cancer. The picture here is genuinely more nuanced than a yes/no answer allows.

Observational studies have noted that people with obesity (the population most likely to be prescribed Wegovy) already carry a higher baseline risk of several cancers, including pancreatic cancer, compared with people at a healthy weight. Untangling whether a medicine adds to that risk, or whether researchers are simply observing the underlying condition, is methodologically difficult. To date, no regulatory body has concluded that semaglutide causes pancreatic cancer. The MHRA's January 2026 Drug Safety Update for GLP-1 medicines focused on acute pancreatitis as a known infrequent but serious risk (not malignancy) and the Yellow Card scheme remains the mechanism for reporting any suspected new signal.

Pancreatitis is worth knowing about in its own right. Severe, persistent stomach pain that seems to reach your back, with or without vomiting, is the symptom to act on quickly. Stop your pen, call 111 or go to A&E, and tell staff you are taking a GLP-1 medicine. This is not a reason to avoid treatment for most people, but it is a reason to be informed. If you have ever wondered whether Wegovy has any effect on libido, our dedicated page explores how hormonal and physiological changes during treatment can affect different aspects of health, including why GI symptoms sometimes intensify after titration steps, a pattern you can follow in detail on our Wegovy dose increase chart.

When you need to get medical help, and what to report

Knowing when to act is the most practical thing this page can give you. During Wegovy treatment, contact your GP or call 111 promptly if you notice any of the following: a new lump or swelling in your neck; persistent hoarseness or difficulty swallowing; severe stomach pain that does not settle; jaundice (yellowing of the skin or eyes); or any symptom that feels unusual and has appeared since starting or changing your dose.

None of these is certain evidence of something serious (most turn out to have a benign explanation) but all deserve a conversation with a clinician rather than a wait-and-see approach. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk allows patients and carers to report suspected side effects directly to the regulator, and that reporting is genuinely how new signals get detected and reviewed. It takes about five minutes from a mobile.

If you are mid-titration and want to understand the schedule in detail, our page covering how and whether your Wegovy dose increases over time may help you distinguish normal adjustment from something that needs attention. For anything urgent, do not wait for an online consultation, call your GP or 111 the same day.

How a prescriber weighs up cancer-related history at consultation

This is where the decision-making framing becomes concrete. The MHRA-approved Wegovy prescribing information lists MTC and MEN2 as absolute contraindications. Beyond those, a prescriber will want to know about any history of GI conditions, pancreatitis, gallbladder disease, or endocrine tumours, not because Wegovy is proven to worsen them, but because shared risk factors mean the clinical picture needs to be read as a whole. Think of it like the conversation a GP has before prescribing almost anything: context matters enormously.

People sometimes ask whether having had a different kind of cancer in the past rules them out. It does not do so automatically. Wegovy's contraindications are specific, and a prescriber who knows your full history is the right person to assess whether treatment makes sense, including questions around what a Wegovy increase involves and whether it is appropriate given your individual circumstances, and our page on whether increasing your Wegovy dose actually increases weight loss gives useful context for those conversations. That is not a deflection, it reflects how licensed prescribing actually works.

At nume, a GPhC-registered prescriber personally reviews every consultation, you can read about our clinical team's approach on the clinical team page. If you have cancer-related questions you want addressed before committing to anything, they are exactly the kind of thing to raise in your free consultation. The prescriber reviews it the same day. No question about your medical history is too detailed to include.